References of "Louis, Edouard"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCapsule Endoscopy in paediatrics: multicentric Belgian study
Urbain, D.; Tresinie, M.; De Looze, D. et al

in Acta Gastro-Enterologica Belgica (2007), 70(1, JAN-MAR), 11-14

Bacground and study aims : Capsule Endoscopy (CE) is a non-invasive procedure for evaluating small bowel disease. Data concerning children are scarce. The aim of the present report was to review all ... [more ▼]

Bacground and study aims : Capsule Endoscopy (CE) is a non-invasive procedure for evaluating small bowel disease. Data concerning children are scarce. The aim of the present report was to review all paediatric cases investigated by CE in Belgium. Patients and methods : The seven Belgian academic hospitals using the CE device (Given) were asked to collect information on CE performed in patients <= 18 years. Main indications for performing VCE, former radiological and endoscopic procedures were collected, as well as final diagnosis and clinical impact of VCE findings. Results : From November 2002 until December 2005, VCE was performed in 17 children (mean age : 11.9 years, range : 5-18). Indications were occult gastro-intestinal bleeding (OGIB) and/or iron deficiency anaemia (IDA) (10 cases) and chronic and/or recurrent abdominal pain (7 cases). Mean duration of symptoms was 8.6 months. The mean number of endoscopic and radiological procedures before performing CE was 4.2 per patient. Detected lesions were ulcerations (6 cases), jejunal varices (1), ileo-ileal invagination (2), active bleeding (1), and normal findings (7). In the indication of OGIB/IDA, relevant findings having an impact on the diagnosis were found in 60% of the cases. In the group with chronic and recurrent abdominal pain, CE brought relevant findings in 43%. CE findings had an impact on therapy in 44% of the patients. Conclusions : CE could be a useful tool for clinical work-up of difficult paediatric cases, not only in the indication of IDA/OGIB, but also for selected cases of recurrent abdominal pain, but prospective controlled trials including emerging techniques like CT enterography are mandatory. [less ▲]

Detailed reference viewed: 25 (0 ULiège)
Full Text
Peer Reviewed
See detailScreening for colorectal cancer in 2006
Piront, Patricia ULiege; Louis, Edouard ULiege; Belaiche, Jacques ULiege et al

in Acta Endoscopica (2007), 37(3), 305-313

Colorectal cancer is the second leading cause of death in Northern countries and needs a national screening program to reduce mortality and improve quality of life. Screening has to be cost-effective and ... [more ▼]

Colorectal cancer is the second leading cause of death in Northern countries and needs a national screening program to reduce mortality and improve quality of life. Screening has to be cost-effective and acceptable for patients. Many screening tools, invasive or not, are existing and often debated: FOBT, sigmoidoscopy and complete colonoscopy. New tools are in development and have to be evaluated in current practice: virtual colonoscopy, new endoscopic technologies, DNA on faeces or proteomics with markers in serum. [less ▲]

Detailed reference viewed: 23 (2 ULiège)
Full Text
Peer Reviewed
See detailContribution of proteomics to colorectal cancer diagnosis
Meuwis, Marie-Alice ULiege; Louis, Edouard ULiege; Merville, Marie-Paule ULiege

in Acta Endoscopica (2007)

Detailed reference viewed: 52 (5 ULiège)
Full Text
Peer Reviewed
See detailPharmacogenetics of infliximab in Crohn's disease
Dideberg, Vinciane ULiege; Louis, Edouard ULiege; Bours, Vincent ULiege

in Acta Endoscopica (2007), 37(4), 521-530

Pharmacogenetic studies will certainly contribute to a better management of medication in inflammatory bowel diseases. Infliximab is the most efficient drug in refractory and fistulising Crohn's disease ... [more ▼]

Pharmacogenetic studies will certainly contribute to a better management of medication in inflammatory bowel diseases. Infliximab is the most efficient drug in refractory and fistulising Crohn's disease. However, about one third of the patients do not respond to this treatment. Several studies have been performed to identify predictive factors of the response to infliximab in CD. We attempt to summarize the current knowledge on the use of infliximab in CD and focus on the result of these studies and more particularly on pharmacogenetic aspects. [less ▲]

Detailed reference viewed: 73 (3 ULiège)
Full Text
Peer Reviewed
See detailImmunogenicity of infliximab: how to handle the problem?
Baert, Filip; De Vos, Martine; Louis, Edouard ULiege et al

in Acta Gastro-Enterologica Belgica (2007), 70(2), 163-70

BACKGROUND: The introduction of infliximab has greatly advanced the therapeutic armamentarium of the inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis. Although the benefit/risk ... [more ▼]

BACKGROUND: The introduction of infliximab has greatly advanced the therapeutic armamentarium of the inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis. Although the benefit/risk ratio for infliximab is positive, of particular concern has been the problem of immunogenicity ascribed to the chimeric properties of the drug. Antibody formation is associated with allergic reactions and loss of response. AIMS AND METHODS: A literature search was undertaken on the magnitude of the problem of immunogenicity and on the clinical consequences. A survey was conducted about the clinical practice and management of acute and delayed allergic reactions to infliximab in different centres in Belgium. For this, a questionnaire was sent to all members of the Belgian IBD research group (n = 38 belonging to 29 centers). RESULTS AND CONCLUSION: Infusion reactions are important immunologic events induced by the presence of a substantial concentration of antibodies against infliximab (ATI) in the serum. Concomitant immunosuppressive treatment may optimize response to infliximab by preventing the formation of antibodies. Steroid administration prior to an infliximab infusion can further reduce the immunogenicity. Probably the most effective strategy to optimize treatment and avoid immunogenicity is maintenance therapy. If infliximab therapy can be discontinued is yet unclear but when treatment goals have been reached, we feel this should be attempted. In the case of relapse, infliximab should be restarted as maintenance long term. Practical guidelines on how to handle the problem of immunogenicity to infliximab are important for clinicians treating patients with IBD. [less ▲]

Detailed reference viewed: 71 (0 ULiège)
Full Text
Peer Reviewed
See detailTreatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study
Louis, Edouard ULiege; Boverie, Jacques ULiege; Dewit, Olivier et al

in Acta Gastro-Enterologica Belgica (2007), 70(1, Jan-Mar), 15-19

Stricturing subocclusive small bowel Crohn's disease (CD) is often an indication for surgery. We embarked on an open label pilot study to assess the safety and efficacy of infliximab in patients with ... [more ▼]

Stricturing subocclusive small bowel Crohn's disease (CD) is often an indication for surgery. We embarked on an open label pilot study to assess the safety and efficacy of infliximab in patients with stricturing subocclusive CD. Patients and methods : A cohort of patients with a documented and symptomatic small bowel stricture caused by CD was studied. Patients had to be refractory to corticosteroids and/or immunosuppressives, and not in need for immediate surgery. The patients were treated by a single infusion of infliximab 5 mg/kg and followed up at w1, w2, w4 and w8. Results : After the 6(th) patients, the study was prematurely discontinued because the predefined safety thresholds of more than 2 surgeries within the first 5 patients was reached. Only two patients completed the 8 weeks study, with a positive response to infliximab and improvement of inflammation confirmed by the CRP and CT scan. Two patients had to be operated early and the last two patients first did well but worsened after one month and were operated 35 and 42 days after infliximab, respectively. No surgical complications occurred in the 4 operated patients. In conclusion, a subset of patients with subocclusive small bowel stricturing CD may benefit from infliximab. [less ▲]

Detailed reference viewed: 60 (5 ULiège)
Full Text
Peer Reviewed
See detailActualites therapeutiques en hepato-gastroenterologie
Belaiche, Jacques ULiege; Delwaide, Jean ULiege; Polus, Marc ULiege et al

in Revue Médicale de Liège (2007), 62(5-6, May-Jun), 303-9

During the last decade, advances in molecular biology and biotechnology allowed, the development of biological treatments aimed at more precise targets. New algorithms in inflammatory bowel diseases ... [more ▼]

During the last decade, advances in molecular biology and biotechnology allowed, the development of biological treatments aimed at more precise targets. New algorithms in inflammatory bowel diseases, chronic hepatitis C and digestive oncology are examples of the marked progress achieved by these therapies. [less ▲]

Detailed reference viewed: 123 (2 ULiège)
Full Text
Peer Reviewed
See detailLes maladies inflammatoires chroniques intestinales : de la génétique au traitement
Louis, Edouard ULiege; Bours, Vincent ULiege; Dideberg, Vinciane ULiege et al

in Revue Médicale de Liège (2007), 62

Detailed reference viewed: 26 (3 ULiège)
Full Text
Peer Reviewed
See detailLes thérapies innovantes au CHU dans les maladies inflammatoires chroniques de l'intestin (MICI)
Belaiche, Jacques ULiege; Chapelier, Nathalie ULiege; Wertz, Sylvie ULiege et al

in Revue Médicale de Liège (2007), 62 Spec No

Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis are frequent illnesses in western countries. They have a dramatic impact on the health-related quality of life. The new biological ... [more ▼]

Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis are frequent illnesses in western countries. They have a dramatic impact on the health-related quality of life. The new biological treatments developed for these diseases are potentially very effective, but are also expensive and may have significant side effects. In the present paper, the authors describe new biological therapies used during the past 10 years at the CHU. More than 20 therapeutic protocols were implemented. These protocols have given the patients the opportunity to gain very rapid access to new efficient therapies, to benefit from promising techniques for the evaluation of their pathology and to be submitted to a close follow-up that frequently called their treatment into question in the light of the most innovative options. [less ▲]

Detailed reference viewed: 138 (5 ULiège)
Full Text
Peer Reviewed
See detailThe Tnf/Adam 17 System: Implication of an Adam 17 Haplotype in the Clinical Response to Infliximab in Crohn's Disease
Dideberg, Vinciane ULiege; Theatre, Emilie ULiege; Farnir, Frédéric ULiege et al

in Pharmacogenetics and Genomics (2006), 16(10), 727-734

Infliximab, a chimeric anti-tumour necrosis factor (TNF)-alpha antibody induces a clinical response in 70% of Crohn's disease patients and the response to infliximab therapy could be partially determined ... [more ▼]

Infliximab, a chimeric anti-tumour necrosis factor (TNF)-alpha antibody induces a clinical response in 70% of Crohn's disease patients and the response to infliximab therapy could be partially determined by genetic factors. The implication of both transmembrane and soluble forms of the TNF-alpha in the mechanism of action of infliximab has been demonstrated. The aim of our work was first to perform a complete study of TNF variants role in the response to infliximab in Crohn's disease. Secondly, considering the role of ADAM 17 in TNF-alpha shedding, the ADAM 17 locus was also studied. The response to infliximab was evaluated in 222 Caucasian Crohn's disease patients with a luminal (n=160) or fistulizing (n=62) form of the disease. Clinical and biological response evaluation was based on the Crohn's Disease Activity Index score and C-reactive protein level evolutions, respectively. The entire TNF gene was sequenced on the complete cohort. Twelve single nucleotide polymorphisms spanning the ADAM 17 locus were studied and haplotypes rebuilt. A clinical response was observed in 64% of the patients and biological response in 77.1% of patients. No association was found between the TNF gene and the response to infliximab. One haplotype in the ADAM 17 region was associated with a clinical response to infliximab in CD patients (adjusted P=0.045). In conclusion, our results exclude, with a reasonable power, an implication of the TNF gene in the response to infliximab in Crohn's disease, but reveal a potential role of the ADAM 17 gene in this response. [less ▲]

Detailed reference viewed: 34 (1 ULiège)
Full Text
Peer Reviewed
See detailLymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study
Dideberg, Vinciane ULiege; Louis, Edouard ULiege; Farnir, Frédéric ULiege et al

in Pharmacogenetics and Genomics (2006), 16(5), 369-373

A haplotype in the lymphotoxin alpha (LTA) gene has been associated with a lack of response to infliximab in a small cohort of Crohn's disease (CD) patients. The present study aimed to confirm the ... [more ▼]

A haplotype in the lymphotoxin alpha (LTA) gene has been associated with a lack of response to infliximab in a small cohort of Crohn's disease (CD) patients. The present study aimed to confirm the implication of this haplotype in the response to infliximab in a larger cohort of Caucasian patients. The response to the first infusion with infliximab was evaluated in 214 Caucasian patients with either luminal (n = 150) or fistulising (n = 64) CD. Clinical response was based on the decrease in CID Activity Index (luminal) or on the evolution in the fistula discharge (fistulising). Biological response was assessed in 139 patients who had elevated C-reactive protein (CRP) before treatment and for whom CRP values were also available after treatment. A positive biological response was defined as a decrease in CRP of at least 25%. The patients were genotyped for six polymorphisms in the LTA gene. A positive clinical response was present in 65.4% of the patients and a positive biological response was observed in 80.6% of the patients. No association was found with any of the studied polymorphisms, nor with the previously published LTA haplotype and the response to infliximab. We could not confirm an association between the LTA locus and clinical or biological response to infliximab in a large cohort of CID patients. Pharmacogenetics and Genomics 16:369-373 (c) 2006 Lippincott Williams [less ▲]

Detailed reference viewed: 55 (3 ULiège)
Full Text
Peer Reviewed
See detailVideo capsule endoscopy in small-bowel malignancy: A multicenter Belgian study
Urbain, D.; De Looze, D.; Demedts, I. et al

in Endoscopy (2006), 38(4), 408-411

Background and Study Aims: Early diagnosis of small-bowel tumors is crucial for therapy. Video capsule endoscopy has improved the diagnosis of small-bowel diseases, but data concerning the role of this ... [more ▼]

Background and Study Aims: Early diagnosis of small-bowel tumors is crucial for therapy. Video capsule endoscopy has improved the diagnosis of small-bowel diseases, but data concerning the role of this technique in detecting small-bowel malignancy are scarce. The aim of this paper was to review all capsule endoscopy findings at Belgian hospitals, in order to evaluate the diagnostic yield of capsule endoscopy in the field of small-bowel malignancy. Patients and Methods: For this retrospective study, the seven Belgian academic hospitals where the device was being used were asked to review the findings obtained by means of video capsule endoscopy, and to collect information about the cases of small-bowel malignancy. Results: In total, 443 capsule endoscopies were performed up to November 2004, and 11 malignant small-bowel processes were detected (2.5%). The most frequent indications for performing capsule endoscopy in those 11 cases were intestinal bleeding of undefined origin or iron-deficiency anemia. The mean number of diagnostic procedures performed before capsule endoscopy was 3.6. The capsule endoscopy results had a diagnostic yield of 1.6% after classical work-up. In 55% of these cases, capsule endoscopy findings had an influence on therapy. Conclusions: Tumors of the small bowel remain a rare condition. Video capsule endoscopy is able to detect tumors undiagnosed by classical procedures in about 1.6% of cases and has an impact on the therapy in 55% of the tumor cases. [less ▲]

Detailed reference viewed: 82 (0 ULiège)
Full Text
Peer Reviewed
See detailNo association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease
Willot, S.; Vermeire, S.; Ohresser, M. et al

in Pharmacogenetics and Genomics (2006), 16(1), 37-42

We recently showed an association between the FCGR3A V/F polymorphism and the biological response [assessed on the basis of a C-reactive protein (CRP) concentration decrease] to infliximab in Crohn's ... [more ▼]

We recently showed an association between the FCGR3A V/F polymorphism and the biological response [assessed on the basis of a C-reactive protein (CRP) concentration decrease] to infliximab in Crohn's disease. The CRP and FCGR3A genes are located on the same 1q23 locus. The present study aimed: 0) to exclude a linkage disequilibrium (LD) between the two genes and 00 to study the association between CRP polymorphisms and the response to infliximab, particularly the decrease in CRP after treatment, in Crohn's disease patients. FCGR3A (V/F) polymorphism and three CRP polymorphisms (- 717G/A, 1444C/T, CRP 4A/G) were determined in 206 healthy blood donors and 189 Crohn's disease patients who had received infliximab for either refractory luminal or fistulizing Crohn's disease. Clinical response was defined as complete, partial or absent according to the same definition as in controlled trials. The biological response was defined on the basis of CRP decrease. There was no LID between CRP and FCGR3A in healthy donors or Crohn's disease patients. CRP polymorphisms had no impact on CRP decrease after infliximab. The proportions of Crohn's disease having a positive clinical or biological response were not statistically different among the various genotypes of CRP polymorphisms. There was no LD between CRP and FCGR3A polymorphisms. CRP polymorphisms were not associated with the response to infliximab in Crohn's disease. Pharmacogenetics and Genomics 16:37-42. (c) 2006 Lippincott Williams [less ▲]

Detailed reference viewed: 52 (1 ULiège)
Full Text
Peer Reviewed
See detailLes IPP au très long cours: le problème est-il uniquement économique?
Vanmeerbeek, Marc ULiege; Louis, Edouard ULiege

in Revue Médicale de Liège (2006), 61(5-6), 483-7

Proton pump inhibitors are among the most prescribed drugs in Belgium, due to the high prevalence of gastrooesophageal reflux disease and significant impairment of health-related well-being. Short-term ... [more ▼]

Proton pump inhibitors are among the most prescribed drugs in Belgium, due to the high prevalence of gastrooesophageal reflux disease and significant impairment of health-related well-being. Short-term and long-term efficacy is superior to that of H2-receptor antagonists. Long-term safety is established. Empirical short-term treatment of symptomatic patients under 50 years of age without alarm signs is acceptable, but endoscopic investigation should always be performed before starting a long-term treatment. Doses for management of low-grade oesophagitis may be tailored to the patient's response. Continuous maintenance of full-dose is recommended for high grade oesophagitis. Surgical alternative is to be discussed with patients. Efficacy and mean cost for insurance plans are comparable. Endoscopic procedures are not yet sufficiently evaluated to be considered. Simple lifestyle advice is still useful. The burden of proton pump inhibitors cost is acceptable if they are prescribed at adequate doses. Cost-effective drugs should be chosen first. [less ▲]

Detailed reference viewed: 205 (22 ULiège)
Full Text
Peer Reviewed
See detailPolymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study.
Louis, Edouard ULiege; Watier, Herve E; Schreiber, Stefan et al

in Pharmacogenetics and Genomics (2006), 16(12), 911-4

Recently, it has been shown that FCGR3A-158 gene polymorphism is associated with biological and possibly clinical response to infliximab in Crohn's disease. We further assessed this association in a ... [more ▼]

Recently, it has been shown that FCGR3A-158 gene polymorphism is associated with biological and possibly clinical response to infliximab in Crohn's disease. We further assessed this association in a subset of 344 patients from the large and well-defined cohort of 573 patients with Crohn's disease from the ACCENT I study. No association could be observed between FCGR3A-158 gene polymorphism and the clinical response to infliximab, which was primarily defined as a decrease of >or=70 points in the Crohn's disease activity index or clinical remission (Crohn's disease activity index <150). We did, however, confirm a trend towards a greater decrease in C-reactive protein after infliximab in V/V homozygotes as compared with V/F heterozygotes and F/F homozygotes (-79.4, -76.5, and -64.3%, respectively, at week 6; P=0.085; one-tailed P=0.043). This finding has no immediate clinical impact but may enhance the understanding of the complex mechanisms of action of anti-tumor necrosis factor agents in Crohn's disease. [less ▲]

Detailed reference viewed: 60 (1 ULiège)
Full Text
See detailDiagnosis of small bowel malabsorption syndromes in adults
Belaiche, Jacques ULiege; Louis, Edouard ULiege

in Acta Gastro-Enterologica Belgica (2006), 69(1, Jan-Mar), 31-37

Patients with malabsorption represent a small proportion of presentations with chronic diarrhea. In spite of some progress, the last twenty years were not very innovating in malabsorption investigations ... [more ▼]

Patients with malabsorption represent a small proportion of presentations with chronic diarrhea. In spite of some progress, the last twenty years were not very innovating in malabsorption investigations. Supporting history may direct investigations toward either the small bowel or pancreas. Serological testing for celiac disease will determine most cases without invasive investigation, but individuals suspected to have small bowel malabsorption, despite negative celiac serology, should have endoscopic distal duodenal biopsies taken to exclude other rare forms of small bowel enteropathy. This strategy has largely supplanted many older tests of small bowel function. [less ▲]

Detailed reference viewed: 31 (2 ULiège)
Full Text
See detailEvolution of the prevalence and characteristics of anemia in inflammatory bowel diseases between 1993 and 2003
Vijverman, A.; Piront, Patricia ULiege; Belaiche, Jacques ULiege et al

in Acta Gastro-Enterologica Belgica (2006), 69(1, Jan-Mar), 1-4

Introduction : Anemia has been considered as an overlooked complication of inflammatory bowel disease. Studies dating back to the 80ties and the 90ties have shown 30% of anemia among inflammatory bowel ... [more ▼]

Introduction : Anemia has been considered as an overlooked complication of inflammatory bowel disease. Studies dating back to the 80ties and the 90ties have shown 30% of anemia among inflammatory bowel disease (IBD) patients. More recently, the broader use of immunosuppressive drug and infliximab allowing better mucosal healing as well as a more aggressive treatment of anemia, including the use of safer form of IV iron, may have influenced the prevalence of anemia among IBD patients. Our aim was to asses the prevalence and characteristics of anemia among two cohorts of IBD patients at 10 years interval and to look for associated clinical or demographic factors. Methods: using the IBD patients register of one senior gastroenterologist, we identified IBD patients he had consecutively seen and who had blood test at the outpatient clinic during the years 1993 and 2003. Demographic and clinical characteristics, treatment for Crohn's disease, blood test results and treatment of anemia were recorded and compared between these two cohorts. Anemia was defined as an hemoglobin level lower than the normal value of the laboratory of our hospital. Results : 80 and 90 patients were identified in 1993 and 2003, respectively. There was no significant difference between the two cohorts, according to age, gender, disease type, duration or location. There were 27/80 (33.8%) and 15/90 (16.7%) anemic patients in 1993 and 2003, respectively (P = 0.013). The prevalence of severe anemia (hemoglobin level < 10.5 g/100 ml) was similar in the two cohorts (6.3% and 5.6%). Characteristics of the anemia were similar in the two cohorts with a majority of iron deficiency anemia and inflammatory anemia. Ferritin and CRP levels were not significantly different in the two cohorts. The only significant difference was a more frequent use of immunosuppressive treatment and infliximab in 2003 than in 1993 (33.3% vs. 13.8%; P = 0.0038, RR :0.41, 0.22-0.77) Conclusions : Prevalence of mild to moderate anemia has significantly decreased in our population over the last 10 years. The only difference detected between the two cohorts was the increased use of immunosuppressive drug (mainly azathioprine). [less ▲]

Detailed reference viewed: 44 (0 ULiège)
Full Text
Peer Reviewed
See detailAtypical symptoms of GORD in Belgium: Epidemiological features, current management and open label treatment with 40 mg esomeprazole for one month
Louis, Edouard ULiege; Jorissen, P.; Bastens, B. et al

in Acta Gastro-Enterologica Belgica (2006), 69(2, Apr-Jun), 203-208

Frequency of atypical symptoms in patients suffering from gastro-oesophageal reflux disease (GORD) is not well known, and the optimal management of such symptoms has not been well established. Our aims ... [more ▼]

Frequency of atypical symptoms in patients suffering from gastro-oesophageal reflux disease (GORD) is not well known, and the optimal management of such symptoms has not been well established. Our aims were to set up an observatory of these atypical symptoms of GORD in Belgium and to study the efficacy of one month treatment with esomeprazole 40 mg. Patients and methods : Gastroenterologists; participating in this observational survey were asked to register every new outpatient with symptoms of GORD during a period of 20 consecutive working days. All patients who reported predominant presence of atypical manifestations of GORD were documented and characterized more in detail. In patients with dominant chest pain or ENT symptoms, a treatment with esomeprazole 40 mg daily during 4 weeks was proposed. Results : 90 gastroenterologists included 2864 patients consulting for symptoms suggestive of GORD, including 776 (27.1%) with dominant atypical symptoms. Endoscopy (performed in 2800 patients) showed significantly less oesophagitis in atypical than in typical GORD patients (68% vs. 81.1%; P < 0.0001). Management of atypical GORD patients appeared to be very heterogeneous. Overall 516/776 patients were included in the open phase of treatment with esomeprazole 40 mg, but data for analysis are only available in 228 patients. After one month, symptoms had disappeared in 57.1% and significantly improved in 26.6%. Conclusion : Atypical GORD represents a large number of consultations in gastroenterology in Belgium. It is associated with less endoscopic lesions than typical GORD. Its management is heterogeneous reflecting the lack of guidelines on this topic. Response rate after esomeprazole 40 mg for one month in this open uncontrolled trial was high. This result warrants confirmation in a placebo-controlled trial. [less ▲]

Detailed reference viewed: 51 (2 ULiège)
Full Text
Peer Reviewed
See detailL'anemie chronique dans les maladies inflammatoires de l'intestin: revue de litterature
Vijverman, A.; Belaiche, Jacques ULiege; Louis, Edouard ULiege

in Revue Médicale de Liège (2005), 60(11), 888-92

Chronic anemia has been considered as an overlooked complication of inflammatory bowel disease (IBD). However it deserves full attention since even mild to moderate anemia has significant impact on ... [more ▼]

Chronic anemia has been considered as an overlooked complication of inflammatory bowel disease (IBD). However it deserves full attention since even mild to moderate anemia has significant impact on quality of life. During the past decade relevant progress has been made in the understanding and treatment of this pathology. In our review, we focus on frequency, mechanisms, diagnosis and treatment of anemia in IBD. [less ▲]

Detailed reference viewed: 88 (0 ULiège)
Full Text
Peer Reviewed
See detailImplication des intolérances et allergies alimentaires dans le syndrome du côlon irritable: quelles sont les evidences?
Ausloos, Floriane ULiege; Belaiche, Jacques ULiege; Louis, Edouard ULiege

in Revue Médicale de Liège (2005), 60(9), 744-9

Irritable Bowel Syndrome (IBS) is a complex and heterogeneous entity that concerns about 1/4 of adults and would be responsible for 50% of gastro-enterology medical consultations. IBS etiopathogenesis and ... [more ▼]

Irritable Bowel Syndrome (IBS) is a complex and heterogeneous entity that concerns about 1/4 of adults and would be responsible for 50% of gastro-enterology medical consultations. IBS etiopathogenesis and physiopathology are not yet fully known. [less ▲]

Detailed reference viewed: 100 (9 ULiège)